JHS Svendgaard Laboratories Ltd
JHS Svendgaard Laboratories Q2 Results 2026 (FY27) statement: Revenue & Margins
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
Top 7 Personal Products companies on management guidance
See the sector's top 10 — free with your mobile number.
JHS Svendgaard Laboratories Ltd Q2 FY27 key numbers
- Revenue
- For the quarter ended 30 September 2026, consolidated revenue from operations was Rs. 2,303.805 lakhs compared to Rs. 2,077.1 lakhs in the same quarter of 2025, which reflects an approximate year-on-year growth of 10.8%.
As stated in JHS Svendgaard Laboratories Ltd's Q2 FY27 results statement · published 2 Nov 2026. Reported figures, not investment advice.
Based on JHS Svendgaard Laboratories Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
For the quarter ended 30 September 2026, consolidated revenue from operations was Rs. 2,303.805 lakhs compared to Rs. 2,077.1 lakhs in the same quarter of 2025, which reflects an approximate year-on-y. EBITDA for the quarter ended 30 September 2026 is Rs. 52.279 lakhs, showing a year-on-year increase of 3.77% from Rs. 50.411 lakhs in the same quarter last year.
From JHS Svendgaard Laboratories Ltd's Q2 FY27 earnings-call transcript · updated 2 Nov 2026.
How did JHS Svendgaard Laboratories' revenue grow in the September 2026 quarter?
- For the quarter ended 30 September 2026, consolidated revenue from operations was Rs. 2,303.805 lakhs compared to Rs. 2,077.1 lakhs in the same quarter of 2025, which reflects an approximate year-on-year growth of 10.8%.
- The standalone revenue for the quarter was Rs. 2,306.78 lakhs, up from Rs. 2,120.01 lakhs in the previous year quarter, showing around 8.87% growth.
- The company operates in the oral care product segment and mentions it as the sole reportable operating segment.
What happened to JHS Svendgaard Laboratories' margins in Q2 FY27?
See what JHS Svendgaard Laboratories Ltd said on profitability & margins — free account, 30 seconds.
What capex is JHS Svendgaard Laboratories planning?
- The company has utilized funds totaling Rs. 2,625 lakhs raised through equity shares for:
- A project in Jammu and Kashmir: Rs. 71.29 lakhs
- Capital expenditure: Rs. 778.18 lakhs
2 more points from JHS Svendgaard Laboratories Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Personal Products
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is JHS Svendgaard Laboratories raising money or cutting debt?
See what JHS Svendgaard Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is JHS Svendgaard Laboratories' order book?
See what JHS Svendgaard Laboratories Ltd said on order book & pipeline — free account, 30 seconds.
JHS Svendgaard Laboratories Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Jun 2026 (Q1 FY27). The Q2 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹30 Cr, net profit ₹1 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What JHS Svendgaard Laboratories's management said in earlier quarters
Others in Personal Products this season
- Aakaar Medical (Q2 FY27)
Revenue from operations in H1 FY27: INR 43.72 Cr, up 72.6% YoY from INR 25.32 Cr in H1 FY26 (Page 12, 11, 4) . Key investor presentation takeaways from Aakaar M
- Godrej Consumer (Q2 FY27)
Consolidated net sales for Q2 FY2027: ₹4,396 crore, up 19% year-on-year; constant currency growth 15% (Page 8) . Key investor presentation takeaways from Godrej
- Colgate-Palmoliv (Q2 FY27)
1,692 crore, up 12.2% year-on-year from Rs. Key results statement takeaways from Colgate-Palmolive (India) Ltd's Q2 FY27 results statement — and how it ranks ag
- Bajaj Consumer (Q2 FY27)
. Key concall takeaways from Bajaj Consumer's Q2 FY27 earnings call — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Personal Products
on management's own guidance
- Strong growth2
- Strong growth1
- Honasa Consumer LtdGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
JHS Svendgaard Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were JHS Svendgaard Laboratories Ltd Q2 FY27 results?
For the quarter ended 30 September 2026, consolidated revenue from operations was Rs. 2,303.805 lakhs compared to Rs. 2,077.1 lakhs in the same quarter of 2025, which reflects an approximate year-on-y. EBITDA for the quarter ended 30 September 2026 is Rs. 52.279 lakhs, showing a year-on-year increase of 3.77% from Rs. 50.411 lakhs in the same quarter last year.
What is JHS Svendgaard Laboratories Ltd share price analysis?
JHS Svendgaard Laboratories Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹72 Cr. Investors should review the full earnings analysis for detailed insights.
Is JHS Svendgaard Laboratories Ltd planning capital expenditure?
The company has utilized funds totaling Rs. 2,625 lakhs raised through equity shares for:.
Keep JHS Svendgaard Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.